Association between urinary prostaglandin E2 metabolite and breast cancer risk: A prospective, case-cohort study of postmenopausal women

Sangmi Kim, Jack A. Taylor, Ginger L. Milne, Dale P. Sandler

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Overweight or obese women are at increased risk of developing and dying from breast cancer. Obesity-driven inflammation may stimulate prostaglandin E2 (PGE2)-mediated aromatase activation and estrogen biosynthesis in breast tissues. We hypothesized that increased production of PGE2 would contribute to elevated breast cancer risk in postmenopausal women. We carried out a case-cohort study with 307 incident breast cancer cases and 300 subcohort members from the Sister Study cohort. HRs and 95% confidence intervals (CI) were estimated for the association between urinary levels of a major PGE2 metabolite (PGE-M) and breast cancer risk using Prentice's pseudo-likelihood approach. Several lifestyle factors were associated with urinary levels of PGE-M: smoking, high-saturated fat diet, and obesity increased urinary PGE-M, and use of nonsteroidal antiinflammatory drugs (NSAID) decreased urinary PGE-M. Although there was no association between urinary PGE-M and postmenopausal breast cancer risk in the overall analysis or among regular users of NSAIDs, there was a positive association among postmenopausal women who did not regularly use NSAIDs with HRs of 2.1 [95% confidence interval (CI): 1.0-4.3]; 2.0 (95%CI: 1.0-3.9); and 2.2 (95% CI: 1.1-4.3) for the second, third, and highest quartiles of PGE-M. Our findings suggest a link between systemic PGE2 formation and postmenopausal breast cancer, and a possible modification of the association by lifestyle and pharmacologic interventions. If confirmed in larger studies, these results may have useful implications for the development of preventive strategies.

Original languageEnglish (US)
Pages (from-to)511-518
Number of pages8
JournalCancer Prevention Research
Volume6
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Dinoprostone
Cohort Studies
Breast Neoplasms
Confidence Intervals
Non-Steroidal Anti-Inflammatory Agents
Life Style
Obesity
Aromatase
High Fat Diet
Siblings
Estrogens
Breast
Anti-Inflammatory Agents
Smoking
Inflammation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association between urinary prostaglandin E2 metabolite and breast cancer risk : A prospective, case-cohort study of postmenopausal women. / Kim, Sangmi; Taylor, Jack A.; Milne, Ginger L.; Sandler, Dale P.

In: Cancer Prevention Research, Vol. 6, No. 6, 01.06.2013, p. 511-518.

Research output: Contribution to journalArticle

Kim, Sangmi ; Taylor, Jack A. ; Milne, Ginger L. ; Sandler, Dale P. / Association between urinary prostaglandin E2 metabolite and breast cancer risk : A prospective, case-cohort study of postmenopausal women. In: Cancer Prevention Research. 2013 ; Vol. 6, No. 6. pp. 511-518.
@article{da64d7ad22204cdb8e89b405949e967c,
title = "Association between urinary prostaglandin E2 metabolite and breast cancer risk: A prospective, case-cohort study of postmenopausal women",
abstract = "Overweight or obese women are at increased risk of developing and dying from breast cancer. Obesity-driven inflammation may stimulate prostaglandin E2 (PGE2)-mediated aromatase activation and estrogen biosynthesis in breast tissues. We hypothesized that increased production of PGE2 would contribute to elevated breast cancer risk in postmenopausal women. We carried out a case-cohort study with 307 incident breast cancer cases and 300 subcohort members from the Sister Study cohort. HRs and 95{\%} confidence intervals (CI) were estimated for the association between urinary levels of a major PGE2 metabolite (PGE-M) and breast cancer risk using Prentice's pseudo-likelihood approach. Several lifestyle factors were associated with urinary levels of PGE-M: smoking, high-saturated fat diet, and obesity increased urinary PGE-M, and use of nonsteroidal antiinflammatory drugs (NSAID) decreased urinary PGE-M. Although there was no association between urinary PGE-M and postmenopausal breast cancer risk in the overall analysis or among regular users of NSAIDs, there was a positive association among postmenopausal women who did not regularly use NSAIDs with HRs of 2.1 [95{\%} confidence interval (CI): 1.0-4.3]; 2.0 (95{\%}CI: 1.0-3.9); and 2.2 (95{\%} CI: 1.1-4.3) for the second, third, and highest quartiles of PGE-M. Our findings suggest a link between systemic PGE2 formation and postmenopausal breast cancer, and a possible modification of the association by lifestyle and pharmacologic interventions. If confirmed in larger studies, these results may have useful implications for the development of preventive strategies.",
author = "Sangmi Kim and Taylor, {Jack A.} and Milne, {Ginger L.} and Sandler, {Dale P.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1158/1940-6207.CAPR-13-0040",
language = "English (US)",
volume = "6",
pages = "511--518",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Association between urinary prostaglandin E2 metabolite and breast cancer risk

T2 - A prospective, case-cohort study of postmenopausal women

AU - Kim, Sangmi

AU - Taylor, Jack A.

AU - Milne, Ginger L.

AU - Sandler, Dale P.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Overweight or obese women are at increased risk of developing and dying from breast cancer. Obesity-driven inflammation may stimulate prostaglandin E2 (PGE2)-mediated aromatase activation and estrogen biosynthesis in breast tissues. We hypothesized that increased production of PGE2 would contribute to elevated breast cancer risk in postmenopausal women. We carried out a case-cohort study with 307 incident breast cancer cases and 300 subcohort members from the Sister Study cohort. HRs and 95% confidence intervals (CI) were estimated for the association between urinary levels of a major PGE2 metabolite (PGE-M) and breast cancer risk using Prentice's pseudo-likelihood approach. Several lifestyle factors were associated with urinary levels of PGE-M: smoking, high-saturated fat diet, and obesity increased urinary PGE-M, and use of nonsteroidal antiinflammatory drugs (NSAID) decreased urinary PGE-M. Although there was no association between urinary PGE-M and postmenopausal breast cancer risk in the overall analysis or among regular users of NSAIDs, there was a positive association among postmenopausal women who did not regularly use NSAIDs with HRs of 2.1 [95% confidence interval (CI): 1.0-4.3]; 2.0 (95%CI: 1.0-3.9); and 2.2 (95% CI: 1.1-4.3) for the second, third, and highest quartiles of PGE-M. Our findings suggest a link between systemic PGE2 formation and postmenopausal breast cancer, and a possible modification of the association by lifestyle and pharmacologic interventions. If confirmed in larger studies, these results may have useful implications for the development of preventive strategies.

AB - Overweight or obese women are at increased risk of developing and dying from breast cancer. Obesity-driven inflammation may stimulate prostaglandin E2 (PGE2)-mediated aromatase activation and estrogen biosynthesis in breast tissues. We hypothesized that increased production of PGE2 would contribute to elevated breast cancer risk in postmenopausal women. We carried out a case-cohort study with 307 incident breast cancer cases and 300 subcohort members from the Sister Study cohort. HRs and 95% confidence intervals (CI) were estimated for the association between urinary levels of a major PGE2 metabolite (PGE-M) and breast cancer risk using Prentice's pseudo-likelihood approach. Several lifestyle factors were associated with urinary levels of PGE-M: smoking, high-saturated fat diet, and obesity increased urinary PGE-M, and use of nonsteroidal antiinflammatory drugs (NSAID) decreased urinary PGE-M. Although there was no association between urinary PGE-M and postmenopausal breast cancer risk in the overall analysis or among regular users of NSAIDs, there was a positive association among postmenopausal women who did not regularly use NSAIDs with HRs of 2.1 [95% confidence interval (CI): 1.0-4.3]; 2.0 (95%CI: 1.0-3.9); and 2.2 (95% CI: 1.1-4.3) for the second, third, and highest quartiles of PGE-M. Our findings suggest a link between systemic PGE2 formation and postmenopausal breast cancer, and a possible modification of the association by lifestyle and pharmacologic interventions. If confirmed in larger studies, these results may have useful implications for the development of preventive strategies.

UR - http://www.scopus.com/inward/record.url?scp=84878887971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878887971&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-13-0040

DO - 10.1158/1940-6207.CAPR-13-0040

M3 - Article

C2 - 23636050

AN - SCOPUS:84878887971

VL - 6

SP - 511

EP - 518

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 6

ER -